Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing. The… Read More
Vancouver, BC – InMed Pharmaceuticals Inc. a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, announced an update regarding BayMedica LLC… Read More
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest… Read More
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years,… Read More
FRANKLIN LAKES, N.J. – BD a leading global medical technology company, announced it has obtained CE Marking for the Revello™ Vascular Covered Stent, a next-generation endovascular solution for the treatment… Read More
